Loading company
Atea Pharmaceuticals, Inc.
AVIR · Nasdaq · ·
Next earnings: November 11, 2026
$5.16-1.1%Sep 29 close
- 1M
- -3.7%
- 6M
- +1.6%
- 1Y
- +77.9%
- 5Y
- -85.3%
AVIR · Nasdaq · ·
Next earnings: November 11, 2026
$5.16-1.1%Sep 29 close
Atea Pharmaceuticals, Inc. is scheduled to report next on November 11, 2026. The date comes from Nasdaq’s earnings calendar, and companies sometimes move it.
The quarter ending June 30, 2026, against the same quarter a year earlier.
| Measure | 3 months toJun 30, 2026 | 3 months toJun 30, 2025 | Change |
|---|---|---|---|
| Profit | -$32.9M | -$37.2M | +11.38% |
| Profit per share | -$0.41 | -$0.44 | +6.82% |
| Free Cash Flow | -$21.5M | $318.5M | -106.76% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
Atea Pharmaceuticals, Inc. has no earnings call transcript available.
“The positive Phase 3 C-BEYOND results announced last month represent a pivotal milestone for Atea, validating BEM/RZR’s potential to become a highly differentiated, best-in-class treatment for hepatitis C virus (HCV),”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Releases land after the close or before the open, so the move is the session that follows.
Ruzasvir for HCV BEM has been shown in in vitro studies to be approximately 10-fold more active than sofosbuvir (SOF) against a panel of laboratory strains and clinical isolates of HCV GT 1–5. In vitro studies have also demonstrated BEM remained fully active against SOF resistance-associated substitutions (S282T), with up to 58-fold more potency than SOF. The pharmacokinetic (PK) profile of BEM supports once-daily dosing for the treatment of HCV. BEM has been shown to have a low risk for drug-drug interactions. BEM has been administered to over 3,200 subjects and has been well-tolerated at doses up to 550 mg for durations up to 12 weeks in healthy subjects and patients. RZR has demonstrated highly potent and pan-genotypic antiviral activity in preclinical (picomolar range) and clinical studies. RZR has been administered to over 3,100 HCV-infected patients at daily doses of up to 180 mg for 12 weeks and has demonstrated a favorable safety profile. The PK profile of RZR supports once-daily dosing.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Atea Pharmaceuticals, Inc.’s Item 2.02 8-K filed August 12, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.